High-risk HPV E5-induced cell fusion: a critical initiating event in the early stage of HPV-associated cervical cancer

Cervical cancer progression is strongly associated with infection of high-risk human papillomavirus (HPV) (e.g., HPV-16 and -18), which are detected in nearly all cervical cancers [1]. HPV is a small, nonenveloped DNA virus expressing three key oncoproteins: E5, E6 and E7, which possess the ability of transforming certain human cells in vitro and are considered to be associated with cervical carcinogenesis in vivo[2‐5]. E6 and E7 are well known for their ability to inhibit the function of tumor suppressors p53 and pRb, respectively [6]. E5 has weak oncogenic properties which occur through increasing epidermal growth factor receptor (EGFR) and inhibiting the expression of major histocompatibility complex (MHC)-I and MHC-II on the plasma membrane [7]. Coexpression of E5 with either E6 or E7, however, promotes transformation by either oncoprotein alone [8].

Recently, the view that oncogenic virus-induced cell fusion may contribute to oncogenesis is appealing as all well-known human oncogenic viruses, including HPV, Hepatitis B virus, Hepatitis C virus, Epstein-Barr virus, Kaposi sarcoma virus and human T-lymphotropic virus type 1, have fusogenic activity [9‐11]. Researches show that although most tetraploid cells resulting from non-oncogenic-induced cell fusion would undergo p53-dependent cell cycle arrest or apoptosis, they, however, survive and might be more prone to chromosomal instability (CIN) if p53 or apoptosis is perturbed [12, 13]. It is notable that all oncogenic viruses mentioned above also possess proteins with these abilities [9]. As to HPV-associated cervical cancer, this mechanism may be operative as HPV-16 E5 was recently found to be necessary and sufficient for the formation of tetraploid cells [10, 11], which are frequently found in precancerous cervical lesions and its formation is strongly associated with HPV state [14, 15].

The fact that aneuploid cells are frequently observed in precancerous lesions with elevated proportion of tetraploid cells, the formation of which is obviously associated with HPV infection [14] suggests that formation of tetraploid cells is a critical event in cervical carcinogenesis, but the detail formation mechanism of tetraploidy is not clear. It is reported that expression of either HPV E6 or E7 alone is sufficient to deregulate cytokinesis and consequently produce tetraploid cells [16, 17]. However, Hu et al. demonstrated that the formation of these cells is primarily attributed to E5 and E5-induced cell fusion, rather than E6, E7 and cytokinesis failure [10].

Tetraploid cells formed by accident can not undergo normal mitosis which would trigger p53-dependent cell cycle arrest or apoptosis [12, 13], whereas, oncogenic virus-induced cell fusion is sufficient to induce CIN when fusion occurs concomitantly with expression of viral oncoproteins capable of perturbing p53 or apoptosis [12]. Consistently, although most tetraploid cells die out, whereas, coexpression of HPV-16 E6/E7 enhances the proliferation of these cells and the likelihood for colony formation elevates 3-fold [10].

Based on the observations mentioned above, we propose that high-risk HPV E5-induced cell fusion may play a critical role in the early stage of HPV-associated cervical cancer. However, it is widely accepted that increasingly deregulated expression of the E6-E7 oncogenes of high-risk HPVs has been identified as the major transforming factor in the pathogenesis of cervical dysplasia and derived cancers [2]. In fact, these two mechanisms are not mutually exclusive as E5 functions only in the early stage, whereas, E6 and E7 act throughout the carcinogenesis. Additionally, it is notable that expression levels of all three oncoproteins in host cell are low for tight restriction in the early stage, and expression of E5 is nearly not detectable in all late stages for integration [3]. Moreover, the ability of E6 and E7 to transform various cells have been demonstrated only in overexpression systems, therefore, whether it also occurs in natural settings is not known. We also notice that in vitro[18, 19] and clinic studies [20] reveal that chromosomal instability and aneuploidization seem to precede and favor integration of HPV genomes, which in turn leads to expression of viral-cellular fusion transcripts and further enhances expression of the E6-E7 genes, which renders transformed cells strong growth advantages [21].

In order to determine whether high-risk HPV E5-induced cell fusion is important for initial transformation, we can compare the likelihood for colony formation or tumorigenic ability in nude mice between normal HaCaT cells expressing all three oncogenic proteins and E5-induced bi-nucleated HaCaT cells expressing E6 and E7. In our hypothesis, cell fusion and cell cycle deregulation are two key events for initiation of transformation. Therefore, inhibition of cell fusion should significantly decrease the likelihood for transformation. Moreover, investigating premature chromosome condensation (PCC) in HPV-positive and negative precancerous cells is another way to test this hypothesis. PCC refers to condensation of interphase chromosomes following fusion between an interphase and a mitotic cell [22], and it can be used as a tool to detect the existence of cell fusion [23].

Understanding the cause of cancer is critical for effective diagnosis, prevention and therapy. The recent view that human oncogenic virus-induced cell fusion can initiate cancer is an appealing mechanism. In this article, we propose that high-risk HPV E5-induced cell fusion is an important event in the early stage of HPV-associated cervical cancer. This viewpoint will change our understanding of the mechanisms by which HPV induces cervical cancer. According to this hypothesis, blocking HPV E5-induced cell fusion is a promising way to prevent the progression of cervical cancer. Additionally, establishment of a role of cell fusion in carcinogenesis of cervical cancer is of reference value for understanding the pathogenesis of other virus-associated cancers.